ethyl 3-(3-cyanophenyl)-2-fluoro-3-methylacrylate | 534576-34-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: ethyl 3-(3-cyanophenyl)-2-fluoro-3-methylacrylate
• 英文别名: ethyl (Z)-3-(3-cyanophenyl)-2-fluorobut-2-enoate
• CAS: 534576-34-6
• 化学式: C₁₃H₁₂FNO₂
• 分子量: 233.242
• InChiKey: ZPUGLCBNWGGQSR-XFXZXTDPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  三甲基铝 、 2-(4-氨基苯基)-N-叔丁基苯磺酰胺 、 ethyl 3-(3-cyanophenyl)-2-fluoro-3-methylacrylate 在 盐酸 作用下， 以 正己烷 、 二氯甲烷 、 水 为溶剂， 生成 (2E)-N-[4-(2-{[(tert-butyl)amino]sulfonyl}phenyl)phenyl]-3-(3-cyanophenyl)-2-fluorobut-2-enamide
  参考文献：
  名称：

  Inhibitors of factor Xa

  摘要：

  披露了新型化合物、它们的盐和与它们相关的组合物，这些化合物对哺乳动物因子Xa具有活性。这些化合物在体外或体内用于预防或治疗凝血障碍。

  公开号：

  US06399627B1
• 作为产物：
  描述：

  2-氟-2-磷酰基乙酸三乙酯 、 3-乙酰苯腈 在 双(三甲基硅烷基)氨基钾 作用下， 生成 (E)-3-(3-Cyano-phenyl)-2-fluoro-but-2-enoic acid ethyl ester 、 ethyl 3-(3-cyanophenyl)-2-fluoro-3-methylacrylate
  参考文献：
  名称：

  Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitors

  摘要：

  Substituted acrylamides were used as templates that bridge P1 and P4 binding elements, resulting in a series of potent sub-nanomolar) and selective factor Xa inhibitors. In this template, cis-geometry of P1 and P4 ligands is highly preferred. SAR on the substituting groups, as well as on modification of P1 and P4 moieties is described. Compounds in this series show good in vivo efficacy in animal models. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00199-3

文献信息

• Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitors
  作者：Yonghong Song、Lane Clizbe、Chhaya Bhakta、Willy Teng、Wenhao Li、Yanhong Wu、Zhaozhong Jon Jia、Penglie Zhang、Lingyan Wang、Brandon Doughan、Ting Su、James Kanter、John Woolfrey、Paul Wong、Brian Huang、Katherine Tran、Uma Sinha、Gary Park、Andrea Reed、John Malinowski、Stan Hollenbach、Robert M. Scarborough、Bing-Yan Zhu

  DOI：10.1016/s0960-894x(02)00199-3

  日期：2002.6

  Substituted acrylamides were used as templates that bridge P1 and P4 binding elements, resulting in a series of potent sub-nanomolar) and selective factor Xa inhibitors. In this template, cis-geometry of P1 and P4 ligands is highly preferred. SAR on the substituting groups, as well as on modification of P1 and P4 moieties is described. Compounds in this series show good in vivo efficacy in animal models. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Design and synthesis of factor Xa inhibitors and their prodrugs
  作者：Yonghong Song、Lane Clizbe、Chhaya Bhakta、Willy Teng、Paul Wong、Brian Huang、Katherine Tran、Uma Sinha、Gary Park、Andrea Reed、Robert M Scarborough、Bing-Yan Zhu

  DOI：10.1016/s0960-894x(02)00921-6

  日期：2003.1

  In addition to our previously reported fluoro acrylamides Xa inhibitors 2 and 3, a series of potent and novel cyclic diimide amidine compounds has been identified. In efforts to improve their oral bioavailability, replacement of the amidine group with methyl amidrazone: gives compounds of moderate potency (14, IC50 = 0.028 muM). In the amidoxime prodrug approach, the amidoxime compounds show good oral bioavailability in rats and dogs. High plasma level of prodrug 26 and significant concentration of active drug 26a were obtained upon oral administration of prodrug 26 in rats. (C) 2002 Elsevier Science Ltd. All rights reserved.
• INHIBITORS OF FACTOR Xa
  申请人：COR THERAPEUTICS, INC.

  公开号：EP1159264A2

  公开（公告）日：2001-12-05
• US6399627B1
  申请人：——

  公开号：US6399627B1

  公开（公告）日：2002-06-04
• [EN] INHIBITORS OF FACTOR Xa<br/>[FR] INHIBITEURS DU FACTEUR Xa
  申请人：COR THERAPEUTICS INC

  公开号：WO2000047554A2

  公开（公告）日：2000-08-17

  Novel compounds of formula in which A is a substituted or unsubstituted phenyl, naphthyl or monocyclic heterocyclic ring, D is a substituted or unsubstituted phenyl or aromatic six-membered heterocyclic ring, K is a substituted or unsubstituted phenyl, naphthyl or bicyclic heterocyclic ring, and the other variables are as defined in the claims, their salts and other derivatives and compositions related thereto having activity against mammalian Factor Xa are disclosed. The coumpounds are useful in vitro or in vivo for preventing or treating coagulation disorders.